STOP-HAE: A Phase 3 Study of ADX-324 in HAE (NCT06960213)
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Who can join: Review the eligibility criteria below.
Location: ADARx Clinical Site — Litchfield Park, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- ADARx Clinical Site — Litchfield Park, Arizona
- ADARx Clinical Site — Little Rock, Arkansas
- ADARx Clinical Site — San Diego, California
- ADARx Clinical Site — Walnut Creek, California
- ADARx Clinical Site — Orlando, Florida
- ADARx Clinical Site — Chevy Chase, Maryland
- ADARx Clinical Site — Wheaton, Maryland
- ADARx Clinical Site — Detroit, Michigan
- ADARx Clinical Site — St Louis, Missouri
- ADARx Clinical Site — Las Vegas, Nevada
- ADARx Clinical Site — New York, New York
- ADARx Clinical Site — Cincinnati, Ohio
- ADARx Clinical Site — Columbus, Ohio
- ADARx Clinical Site — Toledo, Ohio
- ADARx Clinical Site — Hershey, Pennsylvania
- ADARx Clinical Site — Capital Federal, Buenos Aires
- ADARx Clinical Site — Buenos Aires, Buenos Aires F.D.
- ADARx Clinical Site — Adelaide, South Australia
- ADARx Clinical Site — Vienna,
- ADARx Clinical Site — Edegem, Antwerpen
- ADARx Clinical Site — Sofia,
- ADARx Clinical Site — Edmonton, Alberta
- ADARx Clinical Site — Ottawa, Ontario
- ADARx Clinical Site — Montreal, Quebec
- ADARx Clinical Site — Beijing,
📞 Contact the Study Coordinator
Phone: (877) 232-7974
Email: info@adarx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Angioedema
- A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Birmingham, Alabama
- A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) — Paradise Valley, Arizona
- HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Scottsdale, Arizona
- A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema — Birmingham, Alabama
- Berotralstat Treatment in Children With Hereditary Angioedema — Vienna, Ontario
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) — Colorado Springs, Colorado
Explore by condition: All Hereditary Angioedema clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.